# Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)

> **NCT05377905** · PHASE1,PHASE2 · RECRUITING · sponsor: **Falo, Louis, MD** · enrollment: 48 (estimated)

## Conditions studied

- Cutaneous Squamous Cell Carcinoma
- Skin Cancers - Squamous Cell Carcinoma

## Interventions

- **DRUG:** Microneedle Array Doxorubicin (MNA-D)

## Key facts

- **NCT ID:** NCT05377905
- **Lead sponsor:** Falo, Louis, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-13
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05377905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05377905, "Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT05377905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*